Fig. 2: Distribution of the rankings of NF1 manifestation groups as given during the expert consensus meeting and the patient representatives’ survey.
From: Identifying challenges in neurofibromatosis: a modified Delphi procedure
A lower ranking means higher priority for inclusion in clinical trials. Manifestation groups are sorted to the number of votes in the highest priority rankings (rank 1–3). Dotted lines: manifestation group not included in final selection.
